公开(公告)号：US20240382411A1

公开(公告)日：2024-11-21

申请号：US18691672

申请日：2022-09-16

Applicant: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD ,  SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Kangping Guo ,  Lihong Yun ,  Yuanli Wu ,  Yan Huang ,  Hongqin Hu

IPC: A61K9/00 ,  A61K9/08 ,  A61K39/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07K16/28

Abstract: The present application relates to a composition comprising an antigen-binding fragment and an excipient. The antigen-binding fragment comprises an immunoglobulin single variable domain capable of specifically binding to PD-L1 and comprising CDR1-3, the CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 47, and the excipient may comprise proline. The composition has good stability and suitable viscosity and can be used for subcutaneous injection.

公开(公告)号：US11377497B2

公开(公告)日：2022-07-05

申请号：US16479858

申请日：2018-01-23

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Aiwu Zhou ,  Yuhao Jin ,  Ling Wang ,  Jie Wu ,  Hongqin Hu ,  Xiaoxiao Wang

IPC: C07K16/28 ,  C12N15/85 ,  A61K39/395 ,  G01N33/577 ,  G01N33/68

Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.

公开(公告)号：US09969786B2

公开(公告)日：2018-05-15

申请号：US14646926

申请日：2013-11-22

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Kangping Guo ,  Lihong Yun

IPC: C07K14/59 ,  A61K38/24 ,  A61K38/00

CPC classification number: C07K14/59 ,  A61K38/00 ,  A61K38/24 ,  C07K2319/30

Abstract: Disclosed herein is a gonadotropin fusion protein or a thyroid stimulating hormone fusion protein, a method for preparing the same and use thereof. β-subunit of the gonadotropin or thyroid stimulating hormone is fused to an Fc fragment directly or indirectly through a linker, and α-subunit binds to the β-subunit via an affinity between the α-subunit and the β-subunit. The fusion protein has a prolonged half-life and less fluctuating activity.

公开(公告)号：US11225522B2

公开(公告)日：2022-01-18

申请号：US15748421

申请日：2016-08-01

Applicant: Suzhou Alphamab Co., LTD.

Inventor： Ting Xu ,  Yanrong Dong ,  Pilin Wang ,  Ting Chen

IPC: C07K16/28 ,  A61K39/395 ,  C12N5/10 ,  C12N15/85 ,  A61P35/00 ,  A61K45/06 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00 ,  A61N5/10

Abstract: The present invention relates to the field of medical biology and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecule and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.

公开(公告)号：US20190315864A1

公开(公告)日：2019-10-17

申请号：US16302583

申请日：2017-05-19

Applicant: SUZHOU ALPHAMAB CO., LTD. ,  XITIAN ZHANG ,  XIN ZHANG

Inventor： Ting Xu ,  Xiaoxiao Wang ,  Jie Li ,  Haiyan Wu ,  Li Gao ,  Qian Chu ,  Yu Bai

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/22 ,  C07K16/32 ,  A61P35/00 ,  C12N15/70

Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

公开(公告)号：US20220325000A1

公开(公告)日：2022-10-13

申请号：US17639139

申请日：2020-08-28

Applicant: Suzhou Alphamab Co., Ltd.

Inventor： Ting Xu ,  Xiaoxiao Wang ,  Ying Fan ,  Yanrong Dong ,  Liping Chen ,  Jianyun Ji

IPC: C07K16/38 ,  A61P7/04

Abstract: Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.

公开(公告)号：US20220177588A1

公开(公告)日：2022-06-09

申请号：US17369169

申请日：2021-07-07

Applicant: XITIAN ZHANG ,  XIN ZHANG ,  SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Xiaoxiao Wang ,  Jie Li ,  Haiyan Wu ,  Li Gao ,  Qian Chu ,  Yu Bai

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  C07K16/22 ,  C07K16/32 ,  C12N15/70

Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

公开(公告)号：US11091549B2

公开(公告)日：2021-08-17

申请号：US16302583

申请日：2017-05-19

Applicant: SUZHOU ALPHAMAB CO., LTD. ,  XITIAN ZHANG ,  XIN ZHANG

Inventor： Ting Xu ,  Xiaoxiao Wang ,  Jie Li ,  Haiyan Wu ,  Li Gao ,  Qian Chu ,  Yu Bai

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  C07K16/22 ,  C07K16/32 ,  C12N15/70 ,  A61K39/00

Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

公开(公告)号：US20180327494A1

公开(公告)日：2018-11-15

申请号：US15748421

申请日：2016-08-01

Applicant: Suzhou Alphamab Co., LTD.

Inventor： Ting Xu ,  Yanrong Dong ,  Pilin Wang ,  Ting Chen

IPC: C07K16/28 ,  A61K47/68 ,  A61K45/06 ,  A61K39/395 ,  C07K16/30 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C12N5/10 ,  C12N15/85 ,  G01N33/574 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/491 ,  Y02A50/55

Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecular and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.

公开(公告)号：US09708389B2

公开(公告)日：2017-07-18

申请号：US14416817

申请日：2013-07-25

Applicant: SUZHOU ALPHAMAB CO., LTD

Inventor： Ting Xu ,  Tao Xu ,  Xiaoxiao Wang ,  Xinglu Sun ,  Ying Fan ,  Yan Zeng

IPC: A61K39/00 ,  C07K16/00 ,  C12P21/02 ,  A61K39/395

CPC classification number: C07K16/00 ,  A61K39/395 ,  C07K2317/21 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/94 ,  C07K2319/00 ,  C12P21/02

Abstract: The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases.